Joe Duarte

Dr. Joe Duarte has been a professional investor and independent analyst since 1990.  He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.  

Analyst Articles

If the events that unfolded on Sunday, with FBI Director James Comey seeming to cancel any potential legal problems for Democratic presidential candidate Hillary Clinton, are any sign of what’s to come, investors should prepare for an extraordinary election day and post-election market.The Waiting GameIt’s not difficult to get… Read More

In a world where there are no coincidences, there is something prophetic about a late-breaking news story on an otherwise sleepy Friday afternoon – with the following trading day being Halloween – that shakes both the stock market and the presidential election. And yet, as unlikely as any of these… Read More

I am increasingly concerned about the markets as the election nears. As a result, I am recommending a straddle option strategy which will protect our portfolio if there is a major move, either up or down in this market. I will have more on Monday’s BTP weekly. Read More

McKesson (NYSE: MCK) one the largest medical supply wholesalers in the world delivered extremely disappointing earnings after the close on 10/27/16 and the stock delivered a rapid and significant decline falling as low as $140 after closing at $160.50.  Earnings per share came in at $1.34 per share vs. estimates of… Read More

Medidata Solutions (NSDQ: MDSO), a leading provider of cloud-based research trial and recordkeeping software for pharmaceutical and biotech companies, sold off this morning after it delivered better than expected revenues and earnings. The stock initially rallied but eventually succumbed to aggressive selling. This is not an encouraging activity pattern so… Read More

The presidential election is roughly two weeks away, but the war on the pharmaceutical sector has been raging for at least a year and the effects are starting to be felt more acutely across the sector. As a result we are making decisions on key portfolio holdings including our Amgen… Read More

The current market is offering an excellent opportunity to buy protection against election uncertainty and the general trend toward decreasing payments for pharmaceutical companies from Medicare and private insurers. Buy & Johnson December 16, 2016 115 Put Option (JNJ_121616P115) up to $4.   Read More